Literature DB >> 15079759

Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions.

Miguel A Gonzalez-Gay.   

Abstract

OBJECTIVES: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are common and frequently overlapping diseases. In this manuscript similarities and differences between these conditions have been assessed.
METHODS: A retrospective review of the literature was conducted. Reports emphasizing features in common and possible differences are reviewed.
RESULTS: GCA and PMR are characterized by late age at disease onset, are more common in women, exhibit evidence of a systemic inflammatory response, and generally respond well to corticosteroids. In biopsy-proven GCA, PMR manifestations are observed in up to 50% of cases. PMR may be the presenting feature in patients who later develop typical cranial manifestations of GCA. However, PMR manifestations may be observed in diverse conditions other than GCA. Patients with isolated PMR are younger than those with PMR associated to biopsy-proven GCA and exhibit milder inflammatory disease as shown by significantly less abnormality in most laboratory findings. Recent observations have shown that the frequency of pathologic features of GCA in temporal artery biopsies of patients with clinically isolated PMR is less than that previously reported. Besides different steroid requirements, GCA is associated with more vascular complications. Genetic differences, in particular different HLA-DRB1 associations, also have been observed.
CONCLUSIONS: Polymyalgia manifestations may be observed in patients with biopsy-proven GCA, but isolated PMR may be the only clinical feature or the phenotypic expression of a number of conditions. Clinical features and immunogenetic studies show subtle differences between GCA and PMR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15079759     DOI: 10.1016/j.semarthrit.2003.09.007

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  19 in total

Review 1.  Giant cell arteritis: epidemiology, diagnosis, and management.

Authors:  Miguel A Gonzalez-Gay; Cristina Martinez-Dubois; Mario Agudo; Orlando Pompei; Ricardo Blanco; Javier Llorca
Journal:  Curr Rheumatol Rep       Date:  2010-12       Impact factor: 4.592

2.  Clinical guidelines: Best practices and uncertainties in the management of PMR.

Authors:  Miguel A González-Gay; Javier Llorca
Journal:  Nat Rev Rheumatol       Date:  2015-10-20       Impact factor: 20.543

3.  Hepatic involvement in a patient with giant cell arteritis.

Authors:  Ingo Mecklenburg; Veronika Brumberger; Christian Burchardi; Antje Rademacher; Klaus-Jürgen Pfeifer; Christian Folwaczny
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

Review 4.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  Giant cell arteritis.

Authors:  Todd J Schwedt; David W Dodick; Richard J Caselli
Journal:  Curr Pain Headache Rep       Date:  2006-12

Review 6.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 7.  Diagnosis and treatment of giant cell arteritis.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Michele Bertoni; Carlo Salvarani
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  Diagnostic performance of ¹⁸F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis.

Authors:  Florent L Besson; Jean-Jacques Parienti; Boris Bienvenu; John O Prior; Sylvie Costo; Gerard Bouvard; Denis Agostini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-05-11       Impact factor: 9.236

9.  [Positron emission tomography/computed tomography in rheumatology].

Authors:  T Derlin
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

10.  The process from symptom onset to rheumatology clinic in polymyalgia rheumatica.

Authors:  Ediz Dalkılıç; Ayşe Nur Tufan; Emre Hafızoğlu; Merve Hafızoğlu; Fatih Tufan; Ferhat Oksuz; Yavuz Pehlivan; Mustafa Yurtkuran
Journal:  Rheumatol Int       Date:  2014-05-11       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.